Drug Trial Radar · NCT07489755
TGRX-678 Chinese Phase III in Chronic Myelogenous Leukemia (CML) Patients
Last checked: Nov 19, 2026Latest source record: Mar 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Not yet recruiting
Enrollment
180
Planned (sponsor's estimate)
Start
Apr 1, 2026
Primary completion
May 1, 2030
Study completion May 1, 2031
Sponsor
- Lead sponsor
- Shenzhen TargetRx Co., Ltd.Industry
- Sponsor type
- Industry
- First posted
- Mar 24, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A Phase III study evaluating the safety and efficacy of TGRX-678 in CML-CP patients resistant from or intolerant to at least 3 TKIs
Conditions
- Chronic Myelogenous Leukemia
- Chronic Myelogenous Leukemia - Chronic Phase
Interventions
TGRX-678Drug
Patients will be given TGRX-678 for oral administration
TKIDrug
Patient will take TKI of investigator's choice for oral administration
Primary outcomes
What the sponsor says the trial is designed to measure.
- Event-free survival (EFS)Time frame: from randomization to occurance of any of the above-mentioned events (estimated study duration: 5 years)
Locations
No sites are listed on the registry yet.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.